Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?
Bax is a proapoptotic member of the Bcl‐2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respi...
Saved in:
Published in | Journal of neurochemistry Vol. 76; no. 6; pp. 1785 - 1793 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Science Ltd
01.03.2001
Blackwell |
Subjects | |
Online Access | Get full text |
ISSN | 0022-3042 1471-4159 |
DOI | 10.1046/j.1471-4159.2001.00160.x |
Cover
Abstract | Bax is a proapoptotic member of the Bcl‐2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respiratory function, caspase activation and cell death with morphologic features compatible with apoptosis have been observed post mortem in the brain of patients with Parkinson's disease, we tried to clarify the potential role of Bax in this process in an immunohistochemical study on normal and Parkinson's disease post‐mortem brain and primary mesencephalic cell cultures treated with MPP+. We found that Bax is expressed ubiquitously by dopaminergic (DA) neurons in post‐mortem brain of normal and Parkinson's disease subjects as well as in vitro. Using an antibody to Bax inserted into the outer mitochondrial membrane as an index of Bax activation, no significant differences were observed between control and Parkinson's disease subjects, regardless of the mesencephalic subregion analysed. However, in Parkinson's disease subjects, the percentage of Bax‐positive melanized SNpc neurons containing Lewy bodies, suggestive of DA neuronal suffering, was significantly higher than the overall percentage of Bax‐positive neurons among melanized neurons. Furthermore, all melanized SNpc neurons in Parkinson's disease subjects with activated caspase‐3 were also immunoreactive for Bax, suggesting that Bax anchored in the outer mitochondrial membrane of melanized SNpc neurons showing signs of neuronal suffering or apoptosis is increased compared with DA neurons that are apparently unaltered. Surprisingly, MPP+ treatment of tyrosine hydroxylase (TH)‐positive neurons in primary mesencephalic cultures did not cause redistribution of Bax, although cytochrome c was released from the mitochondria and nuclear condensation/fragmentation was induced. Taken together, these findings suggest that in the human pathology, Bax may be a cofactor in caspase activation, but our in vitro data fail to indicate a central role for Bax in apoptotic death of DA neurons in an experimental Parkinson's disease paradigm. |
---|---|
AbstractList | Bax is a proapoptotic member of the Bcl‐2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respiratory function, caspase activation and cell death with morphologic features compatible with apoptosis have been observed post mortem in the brain of patients with Parkinson's disease, we tried to clarify the potential role of Bax in this process in an immunohistochemical study on normal and Parkinson's disease post‐mortem brain and primary mesencephalic cell cultures treated with MPP+. We found that Bax is expressed ubiquitously by dopaminergic (DA) neurons in post‐mortem brain of normal and Parkinson's disease subjects as well as in vitro. Using an antibody to Bax inserted into the outer mitochondrial membrane as an index of Bax activation, no significant differences were observed between control and Parkinson's disease subjects, regardless of the mesencephalic subregion analysed. However, in Parkinson's disease subjects, the percentage of Bax‐positive melanized SNpc neurons containing Lewy bodies, suggestive of DA neuronal suffering, was significantly higher than the overall percentage of Bax‐positive neurons among melanized neurons. Furthermore, all melanized SNpc neurons in Parkinson's disease subjects with activated caspase‐3 were also immunoreactive for Bax, suggesting that Bax anchored in the outer mitochondrial membrane of melanized SNpc neurons showing signs of neuronal suffering or apoptosis is increased compared with DA neurons that are apparently unaltered. Surprisingly, MPP+ treatment of tyrosine hydroxylase (TH)‐positive neurons in primary mesencephalic cultures did not cause redistribution of Bax, although cytochrome c was released from the mitochondria and nuclear condensation/fragmentation was induced. Taken together, these findings suggest that in the human pathology, Bax may be a cofactor in caspase activation, but our in vitro data fail to indicate a central role for Bax in apoptotic death of DA neurons in an experimental Parkinson's disease paradigm. Bax is a proapoptotic member of the Bcl-2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respiratory function, caspase activation and cell death with morphologic features compatible with apoptosis have been observed post mortem in the brain of patients with Parkinson's disease, we tried to clarify the potential role of Bax in this process in an immunohistochemical study on normal and Parkinson's disease post-mortem brain and primary mesencephalic cell cultures treated with MPP(+). We found that Bax is expressed ubiquitously by dopaminergic (DA) neurons in post-mortem brain of normal and Parkinson's disease subjects as well as in vitro. Using an antibody to Bax inserted into the outer mitochondrial membrane as an index of Bax activation, no significant differences were observed between control and Parkinson's disease subjects, regardless of the mesencephalic subregion analysed. However, in Parkinson's disease subjects, the percentage of Bax-positive melanized SNpc neurons containing Lewy bodies, suggestive of DA neuronal suffering, was significantly higher than the overall percentage of Bax-positive neurons among melanized neurons. Furthermore, all melanized SNpc neurons in Parkinson's disease subjects with activated caspase-3 were also immunoreactive for Bax, suggesting that Bax anchored in the outer mitochondrial membrane of melanized SNpc neurons showing signs of neuronal suffering or apoptosis is increased compared with DA neurons that are apparently unaltered. Surprisingly, MPP(+) treatment of tyrosine hydroxylase (TH)-positive neurons in primary mesencephalic cultures did not cause redistribution of Bax, although cytochrome c was released from the mitochondria and nuclear condensation/fragmentation was induced. Taken together, these findings suggest that in the human pathology, Bax may be a cofactor in caspase activation, but our in vitro data fail to indicate a central role for Bax in apoptotic death of DA neurons in an experimental Parkinson's disease paradigm.Bax is a proapoptotic member of the Bcl-2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respiratory function, caspase activation and cell death with morphologic features compatible with apoptosis have been observed post mortem in the brain of patients with Parkinson's disease, we tried to clarify the potential role of Bax in this process in an immunohistochemical study on normal and Parkinson's disease post-mortem brain and primary mesencephalic cell cultures treated with MPP(+). We found that Bax is expressed ubiquitously by dopaminergic (DA) neurons in post-mortem brain of normal and Parkinson's disease subjects as well as in vitro. Using an antibody to Bax inserted into the outer mitochondrial membrane as an index of Bax activation, no significant differences were observed between control and Parkinson's disease subjects, regardless of the mesencephalic subregion analysed. However, in Parkinson's disease subjects, the percentage of Bax-positive melanized SNpc neurons containing Lewy bodies, suggestive of DA neuronal suffering, was significantly higher than the overall percentage of Bax-positive neurons among melanized neurons. Furthermore, all melanized SNpc neurons in Parkinson's disease subjects with activated caspase-3 were also immunoreactive for Bax, suggesting that Bax anchored in the outer mitochondrial membrane of melanized SNpc neurons showing signs of neuronal suffering or apoptosis is increased compared with DA neurons that are apparently unaltered. Surprisingly, MPP(+) treatment of tyrosine hydroxylase (TH)-positive neurons in primary mesencephalic cultures did not cause redistribution of Bax, although cytochrome c was released from the mitochondria and nuclear condensation/fragmentation was induced. Taken together, these findings suggest that in the human pathology, Bax may be a cofactor in caspase activation, but our in vitro data fail to indicate a central role for Bax in apoptotic death of DA neurons in an experimental Parkinson's disease paradigm. Bax is a proapoptotic member of the Bcl‐2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respiratory function, caspase activation and cell death with morphologic features compatible with apoptosis have been observed post mortem in the brain of patients with Parkinson's disease, we tried to clarify the potential role of Bax in this process in an immunohistochemical study on normal and Parkinson's disease post‐mortem brain and primary mesencephalic cell cultures treated with MPP + . We found that Bax is expressed ubiquitously by dopaminergic (DA) neurons in post‐mortem brain of normal and Parkinson's disease subjects as well as in vitro . Using an antibody to Bax inserted into the outer mitochondrial membrane as an index of Bax activation, no significant differences were observed between control and Parkinson's disease subjects, regardless of the mesencephalic subregion analysed. However, in Parkinson's disease subjects, the percentage of Bax‐positive melanized SNpc neurons containing Lewy bodies, suggestive of DA neuronal suffering, was significantly higher than the overall percentage of Bax‐positive neurons among melanized neurons. Furthermore, all melanized SNpc neurons in Parkinson's disease subjects with activated caspase‐3 were also immunoreactive for Bax, suggesting that Bax anchored in the outer mitochondrial membrane of melanized SNpc neurons showing signs of neuronal suffering or apoptosis is increased compared with DA neurons that are apparently unaltered. Surprisingly, MPP + treatment of tyrosine hydroxylase (TH)‐positive neurons in primary mesencephalic cultures did not cause redistribution of Bax, although cytochrome c was released from the mitochondria and nuclear condensation/fragmentation was induced. Taken together, these findings suggest that in the human pathology, Bax may be a cofactor in caspase activation, but our in vitro data fail to indicate a central role for Bax in apoptotic death of DA neurons in an experimental Parkinson's disease paradigm. Bax is a proapoptotic member of the Bcl-2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respiratory function, caspase activation and cell death with morphologic features compatible with apoptosis have been observed post mortem in the brain of patients with Parkinson's disease, we tried to clarify the potential role of Bax in this process in an immunohistochemical study on normal and Parkinson's disease post-mortem brain and primary mesencephalic cell cultures treated with MPP super(+). We found that Bax is expressed ubiquitously by dopaminergic (DA) neurons in post-mortem brain of normal and Parkinson's disease subjects as well as in vitro. Using an antibody to Bax inserted into the outer mitochondrial membrane as an index of Bax activation, no significant differences were observed between control and Parkinson's disease subjects, regardless of the mesencephalic subregion analysed. However, in Parkinson's disease subjects, the percentage of Bax-positive melanized SNpc neurons containing Lewy bodies, suggestive of DA neuronal suffering, was significantly higher than the overall percentage of Bax-positive neurons among melanized neurons. Furthermore, all melanized SNpc neurons in Parkinson's disease subjects with activated caspase-3 were also immunoreactive for Bax, suggesting that Bax anchored in the outer mitochondrial membrane of melanized SNpc neurons showing signs of neuronal suffering or apoptosis is increased compared with DA neurons that are apparently unaltered. Surprisingly, MPP super(+) treatment of tyrosine hydroxylase (TH)-positive neurons in primary mesencephalic cultures did not cause redistribution of Bax, although cytochrome c was released from the mitochondria and nuclear condensation/fragmentation was induced. Taken together, these findings suggest that in the human pathology, Bax may be a cofactor in caspase activation, but our in vitro data fail to indicate a central role for Bax in apoptotic death of DA neurons in an experimental Parkinson's disease paradigm. |
Author | Mouatt‐Prigent, Annick Troadec, Jean‐Denis Faucheux, Baptiste A. Michel, Patrick P. Agid, Yves Hirsch, Etienne C. Hartmann, Andreas Ruberg, Merle |
Author_xml | – sequence: 1 givenname: Andreas surname: Hartmann fullname: Hartmann, Andreas – sequence: 2 givenname: Patrick P. surname: Michel fullname: Michel, Patrick P. – sequence: 3 givenname: Jean‐Denis surname: Troadec fullname: Troadec, Jean‐Denis – sequence: 4 givenname: Annick surname: Mouatt‐Prigent fullname: Mouatt‐Prigent, Annick – sequence: 5 givenname: Baptiste A. surname: Faucheux fullname: Faucheux, Baptiste A. – sequence: 6 givenname: Merle surname: Ruberg fullname: Ruberg, Merle – sequence: 7 givenname: Yves surname: Agid fullname: Agid, Yves – sequence: 8 givenname: Etienne C. surname: Hirsch fullname: Hirsch, Etienne C. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1114763$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11259496$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc1u1DAURi1URKeFV0BeIFgl2E7inwUgGAFtVQELWFs3jkM9JHZqe8T07UmYaYW6KQvLln3ud617TtCRD94ihCkpKan5601Ja0GLmjaqZITQcl6clLtHaHX3cIRWhDBWVKRmx-gkpc0C1Zw-QceUskbViq9Qe57wB9hhwKPLwVwF30UHAx5t5yCHiJ3HMIUph-wM7izkKxx63IUJRudt_DnferuNwacF_Qbxl_Mp-FcJdy5ZSPbdU_S4hyHZZ4f9FP349PH7-qy4_Pr5fP3-sjBNTUmhBDSk6wlXVSXJ_LtWSd5JJWnHWE9axmrBa6qUEKwjFQhTib6yDeVGSdWK6hS93OdOMVxvbcp6dMnYYQBvwzZpwZWUipMHQSpko0QjZ_D5Ady280D0FN0I8Ubfjm8GXhwASAaGPoI3Lv3DzTZ4NWNv95iJIaVoe21chuyCzxHcoCnRi1a90Ys9vdjTi1b9V6vezQHyXsBdi4dL3-xLf7vB3vx3nb74sl5O1R-jpbdR |
CODEN | JONRA9 |
CitedBy_id | crossref_primary_10_1016_j_ejphar_2020_173815 crossref_primary_10_4103_0366_6999_218025 crossref_primary_10_1007_s00702_009_0240_y crossref_primary_10_1089_ars_2011_4074 crossref_primary_10_1111_j_1471_4159_2007_05115_x crossref_primary_10_1007_s11064_008_9876_5 crossref_primary_10_1016_j_bcp_2004_02_007 crossref_primary_10_1113_JP279791 crossref_primary_10_1046_j_1471_4159_2003_01520_x crossref_primary_10_1016_j_bbadis_2009_09_004 crossref_primary_10_1016_j_ejcb_2008_03_003 crossref_primary_10_2174_1573401314666180503153444 crossref_primary_10_1016_S0006_8993_01_03360_1 crossref_primary_10_1016_j_expneurol_2005_04_011 crossref_primary_10_1016_j_neuint_2024_105902 crossref_primary_10_1021_acschemneuro_8b00356 crossref_primary_10_1038_s41531_023_00453_9 crossref_primary_10_1186_s40035_021_00278_7 crossref_primary_10_1016_j_neuroscience_2013_01_050 crossref_primary_10_1007_s10072_014_1700_1 crossref_primary_10_1016_j_bbadis_2013_09_007 crossref_primary_10_1016_j_phytochem_2010_08_015 crossref_primary_10_1016_S0929_6646_09_60380_6 crossref_primary_10_3390_ijms25021182 crossref_primary_10_3748_wjg_v25_i20_2463 crossref_primary_10_1186_1750_1326_7_40 crossref_primary_10_1038_srep25344 crossref_primary_10_1007_s00232_006_0015_4 crossref_primary_10_1007_s00702_007_0765_x crossref_primary_10_1242_dev_01128 crossref_primary_10_1016_S0304_4165_02_00440_3 crossref_primary_10_1089_ars_2020_8229 crossref_primary_10_1007_s11696_018_0664_7 crossref_primary_10_1111_j_1527_3458_2005_tb00269_x crossref_primary_10_1016_j_brainres_2009_10_036 crossref_primary_10_1111_jnc_13706 crossref_primary_10_1007_s12035_023_03849_z crossref_primary_10_1016_S0896_6273_03_00568_3 crossref_primary_10_1016_j_neurol_2023_08_011 crossref_primary_10_1007_s12035_017_0741_x crossref_primary_10_1016_j_neurobiolaging_2013_11_008 crossref_primary_10_3390_ijms22084045 crossref_primary_10_3390_ijms18051012 crossref_primary_10_1016_j_autneu_2007_02_002 crossref_primary_10_1089_rej_2012_1384 crossref_primary_10_1016_j_parkreldis_2008_04_026 crossref_primary_10_1016_j_pharmthera_2011_11_006 crossref_primary_10_1007_s11011_020_00546_x crossref_primary_10_1073_pnas_0609874104 crossref_primary_10_3389_fneur_2018_00347 crossref_primary_10_1016_j_neuroscience_2013_01_007 crossref_primary_10_1038_nrn1100 crossref_primary_10_1016_j_cbi_2014_04_010 crossref_primary_10_1016_j_brainresbull_2003_08_005 crossref_primary_10_1016_j_parkreldis_2007_09_005 crossref_primary_10_1016_j_lfs_2015_11_019 crossref_primary_10_1111_neup_12592 crossref_primary_10_1002_jnr_10539 crossref_primary_10_1016_S1359_6446_03_03000_9 crossref_primary_10_3390_ijms19103082 crossref_primary_10_1016_S0278_5846_03_00025_3 crossref_primary_10_1007_s11033_022_07755_w crossref_primary_10_1155_2012_131058 crossref_primary_10_1016_j_neulet_2010_10_002 crossref_primary_10_1038_gt_2008_88 crossref_primary_10_1007_s00441_004_0954_y crossref_primary_10_1016_j_ijdevneu_2008_01_003 crossref_primary_10_1111_j_1471_4159_2007_04637_x crossref_primary_10_1007_s12035_024_04111_w crossref_primary_10_1016_S1566_2772_01_00021_4 crossref_primary_10_1111_j_1471_4159_2006_04291_x crossref_primary_10_1016_j_bbadis_2009_08_013 crossref_primary_10_1007_s12035_016_0028_7 crossref_primary_10_1016_j_nbd_2009_10_011 crossref_primary_10_1038_s41419_019_2078_z crossref_primary_10_1111_j_1471_4159_2010_07112_x crossref_primary_10_1016_j_expneurol_2016_03_016 crossref_primary_10_1016_j_arr_2021_101263 crossref_primary_10_3233_MNM_180234 crossref_primary_10_4161_auto_28286 crossref_primary_10_31887_DCNS_2004_6_3_ahartmann crossref_primary_10_1007_s00232_004_0654_2 crossref_primary_10_1111_j_1471_4159_2007_05028_x crossref_primary_10_1016_j_molbrainres_2003_08_012 crossref_primary_10_1007_s12035_017_0855_1 crossref_primary_10_1111_jnc_13696 crossref_primary_10_1016_j_bcp_2004_09_018 crossref_primary_10_1186_s13041_016_0230_6 crossref_primary_10_1523_JNEUROSCI_4511_08_2008 crossref_primary_10_1016_j_cellsig_2010_10_020 crossref_primary_10_1111_j_1471_4159_2008_05604_x crossref_primary_10_3390_antiox11112275 crossref_primary_10_1007_s12640_016_9631_7 crossref_primary_10_3390_biom10101421 crossref_primary_10_3390_ijms25189947 crossref_primary_10_1002_ana_10489 crossref_primary_10_1007_s11302_007_9073_z crossref_primary_10_1016_j_pneurobio_2013_04_004 crossref_primary_10_3390_antiox10071069 crossref_primary_10_1007_s11064_008_9747_0 crossref_primary_10_1212_01_wnl_0000198511_09968_b3 |
Cites_doi | 10.1523/JNEUROSCI.19-04-01284.1999 10.1016/0092-8674(93)90509-O 10.1083/jcb.144.5.891 10.1038/74994 10.1016/S0092-8674(00)80434-1 10.1016/0306-4522(96)00100-5 10.1073/pnas.100121097 10.1038/10556 10.1016/s0047-6374(99)00048-2 10.1016/0006-8993(92)91479-X 10.1002/(sici)1097-4547(19981015)54:2<214::aid-jnr9>3.3.co;2-q 10.1093/brain/114.5.2283 10.1002/1531-8257(199903)14:2<383::AID-MDS1037>3.0.CO;2-F 10.1083/jcb.139.5.1281 10.1016/s0306-4522(96)00545-3 10.1016/s0306-4522(98)00154-7 10.1046/j.1460-9568.2000.00966.x 10.1016/S0925-4439(98)00083-0 10.1046/j.1471-4159.1999.0722074.x 10.1016/S0896-6273(00)80173-7 10.1016/s0304-3940(97)00837-9 10.1073/pnas.040556597 10.1038/17135 10.1523/JNEUROSCI.15-10-06364.1995 10.1016/s0140-6736(99)05226-5 10.1016/s0306-4522(97)00640-4 10.1073/pnas.94.14.7531 10.1046/j.1471-4159.1996.67041633.x 10.1038/334345a0 10.1056/NEJM199810153391607 10.1046/j.1471-4159.1998.70062637.x 10.1038/sj.cdd.4400449 10.1073/pnas.94.8.3668 10.1002/ana.410440712 10.1016/s0169-328x(98)00318-0 10.1046/j.1471-4159.1994.63051987.x 10.1523/JNEUROSCI.19-17-07476.1999 10.1038/70237 10.1016/0304-3940(96)12323-5 10.1126/science.270.5233.96 10.1016/0304-3940(94)90271-2 10.1038/sj.onc.1202590 |
ContentType | Journal Article |
Copyright | 2001 INIST-CNRS |
Copyright_xml | – notice: 2001 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TK 7X8 |
DOI | 10.1046/j.1471-4159.2001.00160.x |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef Neurosciences Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Chemistry |
EISSN | 1471-4159 |
EndPage | 1793 |
ExternalDocumentID | 11259496 1114763 10_1046_j_1471_4159_2001_00160_x JNC0160 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 24P 29L 2WC 31~ 33P 36B 3SF 4.4 41~ 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAYJJ AAZKR ABCQN ABCUV ABEML ABIVO ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOD ACGOF ACIWK ACMXC ACNCT ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHEFC AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC FZ0 G-S G.N GAKWD GODZA GX1 H.X HF~ HGLYW HH5 HVGLF HZI HZ~ IH2 IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MVM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI TWZ UB1 V8K VH1 W8V W99 WBKPD WIH WIJ WIK WIN WNSPC WOHZO WOW WQJ WRC WUP WXI WXSBR WYISQ X7M XG1 XJT YFH YNH YOC YUY ZGI ZXP ZZTAW ~IA ~KM ~WT AAYXX AEYWJ AGYGG CITATION AAMMB AEFGJ AGHNM AGQPQ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM PKN 7TK 7X8 |
ID | FETCH-LOGICAL-c5410-97a50df0693380949b986d8981d22f0b224764199772d03a7c37f3e516c989b73 |
IEDL.DBID | DR2 |
ISSN | 0022-3042 |
IngestDate | Fri Jul 11 04:13:15 EDT 2025 Fri Jul 11 04:36:44 EDT 2025 Wed Feb 19 02:34:42 EST 2025 Mon Jul 21 09:13:46 EDT 2025 Thu Apr 24 22:54:32 EDT 2025 Tue Jul 01 02:14:29 EDT 2025 Wed Jan 22 16:29:31 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Cytochrome c Human Nervous system diseases Mitochondria Central nervous system disease Parkinson disease Dopaminergic neuron Degenerative disease Cerebral disorder Extrapyramidal syndrome Apoptosis |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5410-97a50df0693380949b986d8981d22f0b224764199772d03a7c37f3e516c989b73 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1471-4159.2001.00160.x |
PMID | 11259496 |
PQID | 17859758 |
PQPubID | 23462 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_76988960 proquest_miscellaneous_17859758 pubmed_primary_11259496 pascalfrancis_primary_1114763 crossref_citationtrail_10_1046_j_1471_4159_2001_00160_x crossref_primary_10_1046_j_1471_4159_2001_00160_x wiley_primary_10_1046_j_1471_4159_2001_00160_x_JNC0160 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | March 2001 |
PublicationDateYYYYMMDD | 2001-03-01 |
PublicationDate_xml | – month: 03 year: 2001 text: March 2001 |
PublicationDecade | 2000 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
PublicationTitle | Journal of neurochemistry |
PublicationTitleAlternate | J Neurochem |
PublicationYear | 2001 |
Publisher | Blackwell Science Ltd Blackwell |
Publisher_xml | – name: Blackwell Science Ltd – name: Blackwell |
References | 1991; 114 1997; 238 1997; 139 1996; 17 2000; 6 2000; 355 1994; 170 1995; 15 1998; 339 1996; 73 1999; 64 1999; 144 1999; 1 1998; 85 1998; 86 1999; 5 1994; 63 1998; 44 1995; 270 1996; 204 1997; 91 1998; 17 1997; 94 1997; 77 1999; 19 2000; 12 1999; 18 1992; 597 2000; 96 2000; 97 1999; 14 1993; 74 1988; 334 1998; 70 1999; 397 1999; 112 1999; 1453 1999; 72 1998; 5 1998; 54 1996; 67 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_12_1 e_1_2_7_44_1 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_29_1 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_22_1 Michel P. P. (e_1_2_7_28_1) 1999; 18 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_37_1 e_1_2_7_38_1 e_1_2_7_39_1 Putcha G. V. (e_1_2_7_35_1) 1999; 19 |
References_xml | – volume: 597 start-page: 233 year: 1992 end-page: 240 article-title: The glutamate antagonist, MK‐801, does not prevent dopaminergic cell death induced by the 1‐methyl‐4‐phenylpyridinium ion (MPP+) publication-title: Brain Res. – volume: 17 start-page: 3401 year: 1998 end-page: 3415 article-title: Role of hypoxia‐induced Bax translocation and cytochrome release in reoxygenation injury publication-title: Oncogene – volume: 86 start-page: 701 year: 1998 end-page: 707 article-title: Peptide inhibitors of caspase‐3‐like proteases attenuate 1‐methyl‐4‐phenylpyridium‐induced toxicity of cultured fetal rat mesencephalic dopamine neurons publication-title: Neuroscience – volume: 114 start-page: 2283 year: 1991 end-page: 2301 article-title: Ageing and Parkinson's disease: substantia nigra regional selectivity publication-title: Brain – volume: 94 start-page: 7531 year: 1997 end-page: 7536 article-title: Nuclear translocation of NF‐kappaB is increased in dopaminergic neurons of patients with Parkinson disease publication-title: Proc. Natl Acad. Sci. USA – volume: 17 start-page: 1 year: 1996 end-page: 11 article-title: BAX is required for neuronal death after trophic factor deprivation and during development publication-title: Neuron – volume: 85 start-page: 649 year: 1998 end-page: 651 article-title: TUNEL‐positive cells in the substantia nigra of C57BL/6 mice after a single bolus of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine publication-title: Neuroscience – volume: 72 start-page: 2074 year: 1999 end-page: 2082 article-title: Adenosine prevents the death of mesencephalic dopaminergic neurons by a mechanism that involves astrocytes publication-title: J. Neurochem. – volume: 19 start-page: 7476 year: 1999 end-page: 7485 article-title: BAX translocation is a critical event in neuronal apoptosis: regulation by neuroprotectants, BCL‐2, and caspases publication-title: J. Neurosci. – volume: 238 start-page: 78 year: 1997 end-page: 80 article-title: Bcl‐2 and Bax proteins in Lewy bodies from patients with Parkinson's disease and diffuse Lewy body disease publication-title: Neurosci. Lett. – volume: 112 start-page: 5 year: 1999 end-page: 25 article-title: Influence of age on hypoxia/reoxygenation‐induced DNA fragmentation and bcl‐2, bcl‐xl, bax and fas in the rat heart and brain publication-title: Mech. Ageing Dev. – volume: 44 start-page: S72 issue: Suppl. 1 year: 1998 end-page: S84 article-title: Understanding cell death in Parkinson's disease publication-title: Ann. Neurol. – volume: 1 start-page: E209 year: 1999 end-page: E216 article-title: Bcl‐2 proteins: regulators of apoptosis or of mitochondrial homeostasis? publication-title: Nat. Cell Biol. – volume: 1453 start-page: 49 year: 1999 end-page: 62 article-title: The parkinsonian neurotoxin MPP opens the mitochondrial permeability transition pore and releases cytochrome in isolated mitochondria via an oxidative mechanism publication-title: Biochem. Biophys. Acta – volume: 91 start-page: 479 year: 1997 end-page: 489 article-title: Cytochrome and dATP‐dependent formation of Apaf‐1/caspase‐9 complex initiates an apoptotic protease cascade publication-title: Cell – volume: 67 start-page: 1633 year: 1996 end-page: 1642 article-title: Chronic activation of the cyclic AMP signaling pathway promotes development and long‐term survival of mesencephalic dopaminergic neurons publication-title: J. Neurochem. – volume: 19 start-page: 1284 year: 1999 end-page: 1293 article-title: Distinct mechanisms underlie neurotoxin‐mediated cell death in cultured dopaminergic neurons publication-title: J. Neurosci. – volume: 5 start-page: 1004 year: 1998 end-page: 1016 article-title: immunodetection of activated caspase‐3 in apoptotic neurons in the developing nervous system publication-title: Cell. Death Diff. – volume: 54 start-page: 214 year: 1998 end-page: 222 article-title: Involvement of caspase‐like proteinases in apoptosis of neuronal PC12 cells and primary cultured microglia induced by 6‐hydroxydopamine publication-title: J. Neurosci. Res. – volume: 397 start-page: 441 year: 1999 end-page: 446 article-title: Molecular characterization of mitochondrial apoptosis‐inducing factor publication-title: Nature – volume: 94 start-page: 3668 year: 1997 end-page: 3672 article-title: Cytosol‐to‐membrane redistribution of Bax and Bcl‐X(L) during apoptosis publication-title: Proc. Natl Acad. Sci. USA – volume: 5 start-page: 832 year: 1999 end-page: 835 article-title: Inhibition of virus‐induced neuronal apoptosis by Bax publication-title: Nat. Med. – volume: 15 start-page: 6364 year: 1995 end-page: 6376 article-title: Upregulation of bax protein levels in neurons following cerebral ischemia publication-title: J. Neurosci. – volume: 70 start-page: 2637 year: 1998 end-page: 2640 article-title: Caspases mediate 6‐hydoxydopamine‐induced apoptosis but not necrosis in PC12 cells publication-title: J. Neurochem. – volume: 77 start-page: 1037 year: 1997 end-page: 1048 article-title: In situ detection of apoptotic nuclei in the substantia nigra compacta of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining publication-title: Neuroscience – volume: 96 start-page: 6161 year: 2000 end-page: 6166 article-title: Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons publication-title: Proc. Natl Acad. Sci. USA – volume: 74 start-page: 609 year: 1993 end-page: 619 article-title: Bcl‐2 heterodimerizes with a conserved homolog, Bax, that accelerates programmed cell death publication-title: Cell – volume: 12 start-page: 819 year: 2000 end-page: 827 article-title: Differences in bcl‐2‐ and bax‐independent function in regulating apoptosis in sensory neuron populations publication-title: Eur. J. Neurosci. – volume: 64 start-page: 141 year: 1999 end-page: 148 article-title: Caspase‐3‐like proteases and 6‐hydroxydopamine induced cell death publication-title: Brain Res. Mol. Brain Res. – volume: 355 start-page: 389 year: 2000 end-page: 394 article-title: Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects publication-title: Lancet – volume: 63 start-page: 1987 year: 1994 end-page: 1990 article-title: Complex I inhibitors induce dose‐dependent apoptosis in PC12 cells: relevance to Parkinson's disease publication-title: J. Neurochem. – volume: 18 start-page: 503 year: 1999 end-page: 510 article-title: Ventral mesencephalic (dopaminergic) and septal cholinergic neurons publication-title: IBRO Handbook Series – volume: 73 start-page: 979 year: 1996 end-page: 987 article-title: Increased M‐calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? publication-title: Neuroscience – volume: 270 start-page: 96 year: 1995 end-page: 99 article-title: Bax‐deficient mice with lymphoid hyperplasia and male germ cell death publication-title: Science – volume: 144 start-page: 891 year: 1999 end-page: 901 article-title: Bid‐induced conformational change of Bax is responsible for mitochondrial cytochrome release during apoptosis publication-title: J. Cell Biol. – volume: 97 start-page: 2875 year: 2000 end-page: 2880 article-title: Caspase‐3: a vulnerability factor and a final effector in the apoptotic death of dopaminergic neurons in Parkinson's disease publication-title: Proc. Natl Acad. Sci. USA – volume: 334 start-page: 345 year: 1988 end-page: 348 article-title: Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease publication-title: Nature – volume: 6 start-page: 513 year: 2000 end-page: 519 article-title: Mitochondrial control of cell death publication-title: Nat. Med. – volume: 139 start-page: 1281 year: 1997 end-page: 1292 article-title: Movement of Bax from the cytosol to mitochondria during apoptosis publication-title: J. Cell Biol. – volume: 14 start-page: 383 year: 1999 end-page: 385 article-title: Dopaminergic neurons degenerate by apoptosis in Parkinson's disease publication-title: Mov. Disord. – volume: 339 start-page: 1130 year: 1998 end-page: 1143 article-title: Parkinson's disease. Second of two parts publication-title: N. Engl. J. Med. – volume: 204 start-page: 85 year: 1996 end-page: 88 article-title: Increase in Bax expression in substantia nigra following 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) treatment of mice publication-title: Neurosci. Lett. – volume: 170 start-page: 191 year: 1994 end-page: 194 article-title: Apoptosis induced by 1‐methyl‐4‐phenylpyridinium ion (MPP+) in ventral mesencephalic striatal co‐culture in rat publication-title: Neurosci. Lett. – ident: e_1_2_7_25_1 doi: 10.1523/JNEUROSCI.19-04-01284.1999 – ident: e_1_2_7_34_1 doi: 10.1016/0092-8674(93)90509-O – ident: e_1_2_7_6_1 doi: 10.1083/jcb.144.5.891 – ident: e_1_2_7_20_1 doi: 10.1038/74994 – ident: e_1_2_7_24_1 doi: 10.1016/S0092-8674(00)80434-1 – ident: e_1_2_7_32_1 doi: 10.1016/0306-4522(96)00100-5 – ident: e_1_2_7_3_1 doi: 10.1073/pnas.100121097 – ident: e_1_2_7_23_1 doi: 10.1038/10556 – ident: e_1_2_7_2_1 doi: 10.1016/s0047-6374(99)00048-2 – ident: e_1_2_7_26_1 doi: 10.1016/0006-8993(92)91479-X – ident: e_1_2_7_40_1 doi: 10.1002/(sici)1097-4547(19981015)54:2<214::aid-jnr9>3.3.co;2-q – ident: e_1_2_7_9_1 doi: 10.1093/brain/114.5.2283 – ident: e_1_2_7_14_1 doi: 10.1002/1531-8257(199903)14:2<383::AID-MDS1037>3.0.CO;2-F – ident: e_1_2_7_44_1 doi: 10.1083/jcb.139.5.1281 – ident: e_1_2_7_41_1 doi: 10.1016/s0306-4522(96)00545-3 – ident: e_1_2_7_7_1 doi: 10.1016/s0306-4522(98)00154-7 – ident: e_1_2_7_30_1 doi: 10.1046/j.1460-9568.2000.00966.x – ident: e_1_2_7_4_1 doi: 10.1016/S0925-4439(98)00083-0 – ident: e_1_2_7_29_1 doi: 10.1046/j.1471-4159.1999.0722074.x – ident: e_1_2_7_5_1 doi: 10.1016/S0896-6273(00)80173-7 – ident: e_1_2_7_42_1 doi: 10.1016/s0304-3940(97)00837-9 – ident: e_1_2_7_11_1 doi: 10.1073/pnas.040556597 – ident: e_1_2_7_39_1 doi: 10.1038/17135 – ident: e_1_2_7_19_1 doi: 10.1523/JNEUROSCI.15-10-06364.1995 – ident: e_1_2_7_22_1 doi: 10.1016/s0140-6736(99)05226-5 – ident: e_1_2_7_37_1 doi: 10.1016/s0306-4522(97)00640-4 – ident: e_1_2_7_16_1 doi: 10.1073/pnas.94.14.7531 – ident: e_1_2_7_27_1 doi: 10.1046/j.1471-4159.1996.67041633.x – ident: e_1_2_7_13_1 doi: 10.1038/334345a0 – ident: e_1_2_7_21_1 doi: 10.1056/NEJM199810153391607 – ident: e_1_2_7_33_1 doi: 10.1046/j.1471-4159.1998.70062637.x – ident: e_1_2_7_38_1 doi: 10.1038/sj.cdd.4400449 – ident: e_1_2_7_15_1 doi: 10.1073/pnas.94.8.3668 – ident: e_1_2_7_17_1 doi: 10.1002/ana.410440712 – volume: 18 start-page: 503 year: 1999 ident: e_1_2_7_28_1 article-title: Ventral mesencephalic (dopaminergic) and septal cholinergic neurons publication-title: IBRO Handbook Series – ident: e_1_2_7_8_1 doi: 10.1016/s0169-328x(98)00318-0 – ident: e_1_2_7_10_1 doi: 10.1046/j.1471-4159.1994.63051987.x – volume: 19 start-page: 7476 year: 1999 ident: e_1_2_7_35_1 article-title: BAX translocation is a critical event in neuronal apoptosis: regulation by neuroprotectants, BCL‐2, and caspases publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.19-17-07476.1999 – ident: e_1_2_7_43_1 doi: 10.1038/70237 – ident: e_1_2_7_12_1 doi: 10.1016/0304-3940(96)12323-5 – ident: e_1_2_7_18_1 doi: 10.1126/science.270.5233.96 – ident: e_1_2_7_31_1 doi: 10.1016/0304-3940(94)90271-2 – ident: e_1_2_7_36_1 doi: 10.1038/sj.onc.1202590 |
SSID | ssj0016461 |
Score | 2.0662675 |
Snippet | Bax is a proapoptotic member of the Bcl‐2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the... Bax is a proapoptotic member of the Bcl‐2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the... Bax is a proapoptotic member of the Bcl-2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the... |
SourceID | proquest pubmed pascalfrancis crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1785 |
SubjectTerms | 1-Methyl-4-phenylpyridinium - pharmacology Adult Aged Animals apoptosis Apoptosis - physiology Bax bcl-2-Associated X Protein Biological and medical sciences Brain - metabolism Brain - pathology Cells, Cultured cytochrome c Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Dopamine - metabolism Embryo, Mammalian Humans Intracellular Membranes - drug effects Intracellular Membranes - metabolism Lewy Bodies - metabolism Lewy Bodies - pathology Medical sciences Mesencephalon - cytology Mesencephalon - metabolism mitochondria Mitochondria - metabolism MPP Neurology Neurons - drug effects Neurons - metabolism Neurons - pathology Parkinson Disease - metabolism Parkinson Disease - pathology Parkinson's disease Proto-Oncogene Proteins - metabolism Proto-Oncogene Proteins c-bcl-2 Rats Rats, Wistar Reference Values Substantia Nigra - metabolism Substantia Nigra - pathology Tyrosine 3-Monooxygenase - metabolism |
Title | Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1046%2Fj.1471-4159.2001.00160.x https://www.ncbi.nlm.nih.gov/pubmed/11259496 https://www.proquest.com/docview/17859758 https://www.proquest.com/docview/76988960 |
Volume | 76 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9RAEB-kLwpitfUj1dZ9EH3Kkdwm-_Ek9bS0FfsgFvoW9isg9ZLD3EH1r3dmk1w9qVDEtyNkl8tmZvb3y878BuCV5AW6EM9T6X2dYvSbptYFJK5BBe2FKFSsrfp0Jo7Pi9OL8mLIf6JamF4fYv3BjTwjxmtycGP7LiRZVLclJ5fIf3A_JpqXT2LL5AnhyZwLktF__3mtJEUqWvlaOBwNdUjqGQ84b5poY6e6vzAdLlrdd7u4CY5uotu4PR1tw-X4YH1WyuVktbQT9_MPzcf_8-QP4cGAYtlhb3aP4E5odmD3sEEGP__BXrOYVxo_2O_A3dnYU24X7EnH3pkrZtgcIwlG3saTA7BYv4Lsn31tmFm0i2WLEzNP8JS1NfPI7OexShGvRgXOpqNbqWQ7Vq-96dhw0vT2MZwfffgyO06HLg-pKwvcBLQ0ZebrTGhky0g2tdVKeKURSE-ndWYRY0hRUD6MnPqMG-m4rHkoc-G00lbyJ7DVtE14Bswj2vIuaFtzBEqcm0wYbn3pnMIwlBUJyPGNVm6QQKdOHN-qeBRfiEiFZF7R0lKDzryKS1tdJZCvRy56GZBbjNnfMJrrgchBMawn8HI0ogpfAx3UmCa0q67KpUKeV6q_3yGFVgrJZwJPe-v7bXIktIUWCYhoQ7f-u9Xp2Yx-7f3rwOdw7zpB7wVsLb-vwj4itqU9QF88-XgQPfIXhgUvEg |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9RAFD5IfaggXlovUWvnQfQpa7KTzOVJ6mLZ1nYfpIW-hbkFit1kabLQ9td7ZpJsXalQxLcQMkMyOefM9825AXzgNEMVomnMrS1jtH7jWBuHxNUJJy1jmQi5VcczNj3NDs_ys74dkM-F6epDrA7cvGYEe-0V3B9If-7dkr2WcyRAuCF7npeOQs_kEQLKh8Fd5xHSj1UtKV9HK12VDkdR7cN6BhfnXTOt7VWPF6rBZSu7fhd3AdJ1fBs2qP2ncDF8WheX8nO0bPXI3PxR9fE_ffszeNIDWbLXSd5zeOCqLdjeq5DEz6_JRxJCS8OZ_RZsToa2ctugDxryVV0RReZoTND4VtbrAAkpLG19Sc4rohb1oq1xYmI9QiV1SSyS-3lIVMS7oQhn1fhHfdZ2SGD71JDe2fTlBZzufzuZTOO-0UNs8gz3AclVntgyYRIJM_JNqaVgVkjE0uNxmWiEGZxlPiSGj21CFTeUl9TlKTNSSM3pS9io6sq9BmIRcFnjpC4pYiVKVcIU1TY3RqAlSrII-PBLC9NXQffNOC6K4I3PWGBDPC380voenWkRlra4iiBdjVx0lUDuMWZnTWpuByINRcsewe4gRQX-Bu-rUZWrl02RcoFULxd_f4IzKQTyzwhedeL32-TIaTPJImBBiO79usXhbOKv3vzrwF3YnJ4cHxVHB7Pvb-HRbbzeO9hoL5duBwFcq98HxfwFYW4yNw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9RAFD5ICyqI1dZLrLXzIPqUbbIzmcuT1NWlrbqIWOhbmMlMQOomwexC66_3zCTZulKhiG9LyAybybl8X84N4KWgDFWIprGwtozR-o1jUzgkrk46ZTlnMtRWfZrxo1N2cpad9flPvham6w-x-uDmNSPYa6_gjS0P-qhkr-QC-Q_6Y0_z0lEYmTxCPLnJOHpND5C-rFpJ-TZa6apzOEpqn9UzRDiv22nNVd1rdIunVnbjLq7Do-vwNvin6RacD0_WpaWcj5YLMyp-_tH08f88-gO438NYctjJ3UO45apt2DmskMLPL8krEhJLwxf7bbgzGYbK7YA5bslbfUE0maMpQdNbWa8BJBSwIP0n3yqim7pZ1LgxsR6fkrokFqn9PJQp4tXQgrNq_a2-ZjuUr71uSR9qevMITqfvv06O4n7MQ1xkDL2AEjpLbJlwhXQZ2aYySnIrFSLp8bhMDIIMwZlPiBFjm1AtCipK6rKUF0oqI-hj2Kjqyj0FYhFu2cIpU1JESpTqhGtqbFYUEu1QwiIQwxvNi74Huh_F8T0PsXjGAxcSae6P1k_oTPNwtPlFBOlqZdP1AbnBmr01oblaiCQU7XoE-4MQ5fgafKRGV65etnkqJBK9TP79DsGVlMg-I3jSSd9vmyOjZYpHwIMM3fjv5iezif_17F8X7sPtz--m-cfj2YdduHuVrPccNhY_lm4P0dvCvAhq-QuIUzDm |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Is+Bax+a+mitochondrial+mediator+in+apoptotic+death+of+dopaminergic+neurons+in+Parkinson%27s+disease%3F&rft.jtitle=Journal+of+neurochemistry&rft.au=Hartmann%2C+Andreas&rft.au=Michel%2C+Patrick+P.&rft.au=Troadec%2C+Jean%E2%80%90Denis&rft.au=Mouatt%E2%80%90Prigent%2C+Annick&rft.date=2001-03-01&rft.pub=Blackwell+Science+Ltd&rft.issn=0022-3042&rft.eissn=1471-4159&rft.volume=76&rft.issue=6&rft.spage=1785&rft.epage=1793&rft_id=info:doi/10.1046%2Fj.1471-4159.2001.00160.x&rft.externalDBID=10.1046%252Fj.1471-4159.2001.00160.x&rft.externalDocID=JNC0160 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3042&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3042&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3042&client=summon |